Skip to main content
Premium Trial:

Request an Annual Quote

SurroMed Renews Biomarker Collaboration with Merck

NEW YORK, July 7 (GenomeWeb News) - SurroMed has renewed a previously undisclosed biomarker research agreement with Merck, the company said today.

 

SurroMed, based in Menlo Park, Calif., will analyze preclinical samples provided by Merck using its proteomics platform, and will analyze the data to identify candidate biological markers using its informatics tools.

 

The company's other biomarker collaborations include Biogen, Bruker Daltonics, PPD, InterMune, and Eli Lilly.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more